NeuroMetrix Seeks FDA Approval for New Pain Therapy Device

NeuroMetrix has announced it has filed an FDA 510(k) application for its SENSUS pain therapy device, according to a news release.


SENSUS is a non-invasive transcutaneous electrical nerve stimulator intended to be used for the symptomatic relief and management of chronic intractable pain, such as diabetic neuropathy, according to the company.


"The filing of a 510(k) for SENSUS represents a key milestone in this product development program," said Shai N. Gozani, MD, PhD, president and CEO of NeuroMetrix, in the release. "We look forward to feedback from the FDA and working towards a timely clearance. Once commercialized, we believe that SENSUS will complement NC-stat DPNCheck, our sural nerve conduction test for DPN, and move us towards our goal of creating a unique and valuable diabetic neuropathy product portfolio and franchise."


NeuroMetrix is based out of Waltham, Mass.


Related Articles on FDA Clearances:

Devon Medical Products Receives FDA 510(k) Clearance for extriCARE 2400 Negative Pressure Wound Therapy System

Custom Spine Receives FDA 510(k) Clearance for Securis Cannulated Screw System

Spacelabs Healthcare Receives FDA 510(k) Clearance for qube Patient Monitor

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast